Is RDNT or OMDA more profitable?

RadNet has a net margin of -0.66% compared to Omada Health's net margin of -2.22%. RadNet's return on equity of 2.77% beat Omada Health's return on equity. Company Net Margins Return on Equity Return on Assets RadNet -0.66% 2.77% 0.97% Omada Health -2.22% -1.82% -1.36%

Does the media favor RDNT or OMDA?

In the previous week, RadNet had 3 more articles in the media than Omada Health. MarketBeat recorded 5 mentions for RadNet and 2 mentions for Omada Health. Omada Health's average media sentiment score of 1.24 beat RadNet's score of 0.68 indicating that Omada Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RadNet 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omada Health 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, VCYT or OMDA?

Veracyte has higher revenue and earnings than Omada Health. Omada Health is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veracyte $517.15M 7.16 $66.35M $1.41 32.91 Omada Health $283.30M 4.23 -$12.78M -$0.27 N/A

Is VCYT or OMDA more profitable?

Veracyte has a net margin of 20.37% compared to Omada Health's net margin of -2.22%. Veracyte's return on equity of 9.26% beat Omada Health's return on equity. Company Net Margins Return on Equity Return on Assets Veracyte 20.37% 9.26% 8.61% Omada Health -2.22% -1.82% -1.36%

Does the media prefer VCYT or OMDA?

In the previous week, Veracyte had 20 more articles in the media than Omada Health. MarketBeat recorded 22 mentions for Veracyte and 2 mentions for Omada Health. Omada Health's average media sentiment score of 1.24 beat Veracyte's score of 0.57 indicating that Omada Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 7 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Omada Health 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OMDA or CAI?

In the previous week, Caris Life Sciences had 3 more articles in the media than Omada Health. MarketBeat recorded 5 mentions for Caris Life Sciences and 2 mentions for Omada Health. Caris Life Sciences' average media sentiment score of 1.76 beat Omada Health's score of 1.24 indicating that Caris Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omada Health 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Caris Life Sciences 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer DFTX or OMDA?

In the previous week, Definium Therapeutics had 3 more articles in the media than Omada Health. MarketBeat recorded 5 mentions for Definium Therapeutics and 2 mentions for Omada Health. Omada Health's average media sentiment score of 1.24 beat Definium Therapeutics' score of 0.38 indicating that Omada Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Omada Health 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LFST or OMDA?

In the previous week, LifeStance Health Group had 2 more articles in the media than Omada Health. MarketBeat recorded 4 mentions for LifeStance Health Group and 2 mentions for Omada Health. LifeStance Health Group's average media sentiment score of 1.39 beat Omada Health's score of 1.24 indicating that LifeStance Health Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeStance Health Group 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omada Health 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Omada Health (OMDA) Competitors

$20.18 -0.33 (-1.61%)

Closing price 04:00 PM Eastern

Extended Trading

$20.18 0.00 (0.00%)

As of 04:22 PM Eastern

Compare

OMDA vs. RDNT, VCYT, CAI, DFTX, and LFST

Should you buy Omada Health stock or one of its competitors? MarketBeat compares Omada Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Omada Health include RadNet (RDNT), Veracyte (VCYT), Caris Life Sciences (CAI), Definium Therapeutics (DFTX), and LifeStance Health Group (LFST).

How does Omada Health compare to RadNet?

RadNet (NASDAQ:RDNT) and Omada Health (NASDAQ:OMDA) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

RadNet has a net margin of -0.66% compared to Omada Health's net margin of -2.22%. RadNet's return on equity of 2.77% beat Omada Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RadNet	-0.66%	2.77%	0.97%
Omada Health	-2.22%	-1.82%	-1.36%

In the previous week, RadNet had 3 more articles in the media than Omada Health. MarketBeat recorded 5 mentions for RadNet and 2 mentions for Omada Health. Omada Health's average media sentiment score of 1.24 beat RadNet's score of 0.68 indicating that Omada Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RadNet	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omada Health	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Omada Health has lower revenue, but higher earnings than RadNet. RadNet is trading at a lower price-to-earnings ratio than Omada Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RadNet	$2.04B	2.67	-$18.65M	-$0.18	N/A
Omada Health	$283.30M	4.23	-$12.78M	-$0.27	N/A

77.9% of RadNet shares are held by institutional investors. 5.1% of RadNet shares are held by insiders. Comparatively, 6.4% of Omada Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

RadNet has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, Omada Health has a beta of 1.73, meaning that its stock price is 73% more volatile than the broader market.

RadNet currently has a consensus target price of $87.43, suggesting a potential upside of 26.31%. Omada Health has a consensus target price of $24.75, suggesting a potential upside of 22.65%. Given RadNet's stronger consensus rating and higher possible upside, equities research analysts clearly believe RadNet is more favorable than Omada Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RadNet	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.80
Omada Health	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

RadNet beats Omada Health on 10 of the 17 factors compared between the two stocks.

How does Omada Health compare to Veracyte?

Veracyte (NASDAQ:VCYT) and Omada Health (NASDAQ:OMDA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

Veracyte has higher revenue and earnings than Omada Health. Omada Health is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	7.16	$66.35M	$1.41	32.91
Omada Health	$283.30M	4.23	-$12.78M	-$0.27	N/A

Veracyte currently has a consensus price target of $54.33, indicating a potential upside of 17.07%. Omada Health has a consensus price target of $24.75, indicating a potential upside of 22.65%. Given Omada Health's stronger consensus rating and higher probable upside, analysts plainly believe Omada Health is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Omada Health	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Veracyte has a net margin of 20.37% compared to Omada Health's net margin of -2.22%. Veracyte's return on equity of 9.26% beat Omada Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
Omada Health	-2.22%	-1.82%	-1.36%

In the previous week, Veracyte had 20 more articles in the media than Omada Health. MarketBeat recorded 22 mentions for Veracyte and 2 mentions for Omada Health. Omada Health's average media sentiment score of 1.24 beat Veracyte's score of 0.57 indicating that Omada Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	7 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Omada Health	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veracyte has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market. Comparatively, Omada Health has a beta of 1.73, indicating that its stock price is 73% more volatile than the broader market.

Summary

Veracyte beats Omada Health on 11 of the 15 factors compared between the two stocks.

How does Omada Health compare to Caris Life Sciences?

Omada Health (NASDAQ:OMDA) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Omada Health has a beta of 1.73, suggesting that its share price is 73% more volatile than the broader market. Comparatively, Caris Life Sciences has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

Omada Health presently has a consensus target price of $24.75, indicating a potential upside of 22.65%. Caris Life Sciences has a consensus target price of $26.11, indicating a potential upside of 62.18%. Given Caris Life Sciences' higher probable upside, analysts clearly believe Caris Life Sciences is more favorable than Omada Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omada Health	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

In the previous week, Caris Life Sciences had 3 more articles in the media than Omada Health. MarketBeat recorded 5 mentions for Caris Life Sciences and 2 mentions for Omada Health. Caris Life Sciences' average media sentiment score of 1.76 beat Omada Health's score of 1.24 indicating that Caris Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omada Health	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caris Life Sciences	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Caris Life Sciences has a net margin of 3.75% compared to Omada Health's net margin of -2.22%. Caris Life Sciences' return on equity of 98.28% beat Omada Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omada Health	-2.22%	-1.82%	-1.36%
Caris Life Sciences	3.75%	98.28%	48.87%

Omada Health has higher earnings, but lower revenue than Caris Life Sciences. Omada Health is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omada Health	$283.30M	4.23	-$12.78M	-$0.27	N/A
Caris Life Sciences	$812.03M	5.60	-$68.09M	-$7.61	N/A

Summary

Caris Life Sciences beats Omada Health on 9 of the 14 factors compared between the two stocks.

How does Omada Health compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Omada Health (NASDAQ:OMDA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

In the previous week, Definium Therapeutics had 3 more articles in the media than Omada Health. MarketBeat recorded 5 mentions for Definium Therapeutics and 2 mentions for Omada Health. Omada Health's average media sentiment score of 1.24 beat Definium Therapeutics' score of 0.38 indicating that Omada Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Omada Health	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Omada Health has higher revenue and earnings than Definium Therapeutics. Omada Health is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A
Omada Health	$283.30M	4.23	-$12.78M	-$0.27	N/A

Definium Therapeutics has a net margin of 0.00% compared to Omada Health's net margin of -2.22%. Omada Health's return on equity of -1.82% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-100.30%	-69.22%
Omada Health	-2.22%	-1.82%	-1.36%

27.9% of Definium Therapeutics shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by company insiders. Comparatively, 6.4% of Omada Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Definium Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market. Comparatively, Omada Health has a beta of 1.73, suggesting that its stock price is 73% more volatile than the broader market.

Definium Therapeutics currently has a consensus target price of $54.85, suggesting a potential upside of 29.60%. Omada Health has a consensus target price of $24.75, suggesting a potential upside of 22.65%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Definium Therapeutics is more favorable than Omada Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	3.00
Omada Health	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Definium Therapeutics beats Omada Health on 9 of the 16 factors compared between the two stocks.

How does Omada Health compare to LifeStance Health Group?

LifeStance Health Group (NASDAQ:LFST) and Omada Health (NASDAQ:OMDA) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

LifeStance Health Group has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, Omada Health has a beta of 1.73, suggesting that its stock price is 73% more volatile than the broader market.

LifeStance Health Group currently has a consensus price target of $11.50, suggesting a potential upside of 12.09%. Omada Health has a consensus price target of $24.75, suggesting a potential upside of 22.65%. Given Omada Health's higher possible upside, analysts clearly believe Omada Health is more favorable than LifeStance Health Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeStance Health Group	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
Omada Health	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

85.5% of LifeStance Health Group shares are held by institutional investors. 3.5% of LifeStance Health Group shares are held by company insiders. Comparatively, 6.4% of Omada Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, LifeStance Health Group had 2 more articles in the media than Omada Health. MarketBeat recorded 4 mentions for LifeStance Health Group and 2 mentions for Omada Health. LifeStance Health Group's average media sentiment score of 1.39 beat Omada Health's score of 1.24 indicating that LifeStance Health Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeStance Health Group	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omada Health	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LifeStance Health Group has a net margin of 1.55% compared to Omada Health's net margin of -2.22%. LifeStance Health Group's return on equity of 1.56% beat Omada Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeStance Health Group	1.55%	1.56%	1.07%
Omada Health	-2.22%	-1.82%	-1.36%

LifeStance Health Group has higher revenue and earnings than Omada Health. Omada Health is trading at a lower price-to-earnings ratio than LifeStance Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeStance Health Group	$1.42B	2.79	$9.66M	$0.06	171.00
Omada Health	$283.30M	4.23	-$12.78M	-$0.27	N/A

Summary

LifeStance Health Group beats Omada Health on 12 of the 17 factors compared between the two stocks.

Get Omada Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OMDA vs. The Competition

Export

Metric	Omada Health	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.20B	$9.88B	$6.80B	$13.02B
Dividend Yield	N/A	2.54%	2.60%	10.03%
P/E Ratio	-74.74	25.64	279.72	25.54
Price / Sales	4.23	4.84	648.69	115.96
Price / Cash	N/A	26.44	28.64	34.82
Price / Book	5.08	5.19	11.12	6.36
Net Income	-$12.78M	$312.25M	$3.48B	$347.58M
7 Day Performance	-1.22%	-0.83%	2.58%	3.16%
1 Month Performance	-9.87%	-0.82%	-2.79%	-2.06%
1 Year Performance	13.12%	25.00%	64.28%	21.19%

Omada Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OMDA Omada Health	3.0809 of 5 stars	$20.18 -1.6%	$24.75 +22.6%	+18.0%	$1.20B	$283.30M	N/A	849	Positive News Analyst Forecast
RDNT RadNet	3.4684 of 5 stars	$61.51 -0.1%	$87.43 +42.1%	+22.1%	$4.84B	$2.04B	N/A	11,264	Positive News Upcoming Earnings
VCYT Veracyte	3.8799 of 5 stars	$55.61 -1.8%	$55.88 +0.5%	+89.7%	$4.52B	$517.15M	51.02	790	Positive News Earnings Report Analyst Forecast
CAI Caris Life Sciences	4.895 of 5 stars	$15.63 +0.7%	$26.11 +67.1%	N/A	$4.39B	$812.03M	N/A	1,846	News Coverage Positive News
DFTX Definium Therapeutics	3.5131 of 5 stars	$42.65 -1.2%	$52.36 +22.8%	+395.1%	$4.30B	N/A	N/A	40	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OMDA) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Omada Health (OMDA) Competitors

OMDA vs. RDNT, VCYT, CAI, DFTX, and LFST

How does Omada Health compare to RadNet?

Summary

How does Omada Health compare to Veracyte?

Summary

How does Omada Health compare to Caris Life Sciences?

Summary

How does Omada Health compare to Definium Therapeutics?

Summary

How does Omada Health compare to LifeStance Health Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMDA vs. The Competition

Omada Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Omada Health (OMDA) Competitors

OMDA vs. RDNT, VCYT, CAI, DFTX, and LFST

How does Omada Health compare to RadNet?

Is RDNT or OMDA more profitable?

Does the media favor RDNT or OMDA?

Which has higher valuation & earnings, RDNT or OMDA?

Do institutionals & insiders hold more shares of RDNT or OMDA?

Which has more volatility and risk, RDNT or OMDA?

Do analysts prefer RDNT or OMDA?

Summary

How does Omada Health compare to Veracyte?

Which has stronger valuation & earnings, VCYT or OMDA?

Do analysts recommend VCYT or OMDA?

Is VCYT or OMDA more profitable?

Does the media prefer VCYT or OMDA?

Which has more risk & volatility, VCYT or OMDA?

Summary

How does Omada Health compare to Caris Life Sciences?

Which has more volatility and risk, OMDA or CAI?

Do analysts recommend OMDA or CAI?

Does the media favor OMDA or CAI?

Is OMDA or CAI more profitable?

Which has preferable earnings & valuation, OMDA or CAI?

Summary

How does Omada Health compare to Definium Therapeutics?

Does the media prefer DFTX or OMDA?

Which has higher earnings and valuation, DFTX or OMDA?

Is DFTX or OMDA more profitable?

Do institutionals & insiders hold more shares of DFTX or OMDA?

Which has more risk and volatility, DFTX or OMDA?

Do analysts rate DFTX or OMDA?

Summary

How does Omada Health compare to LifeStance Health Group?

Which has more volatility & risk, LFST or OMDA?

Do analysts prefer LFST or OMDA?

Do insiders & institutionals hold more shares of LFST or OMDA?

Does the media favor LFST or OMDA?

Is LFST or OMDA more profitable?

Which has stronger earnings and valuation, LFST or OMDA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMDA vs. The Competition

Omada Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools